Clincosm LogoSign in Get a demo

Lymphoma, Non-Hodgkin

Showing NaN - NaN of 40
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lymphoma, Non-Hodgkin Trial in Worldwide (Copanlisib (BAY80-6946), Placebo, Rituximab)

Active, not recruiting
  • Lymphoma, Non-Hodgkin
  • Copanlisib (BAY80-6946)
  • +7 more
  • Chandler, Arizona
  • +199 more
Jan 31, 2023

Non-Hodgkin's Lymphoma, Relapsed, Chronic Lymphoid Leukemia in Relapse, Non-Hodgkin's Lymphoma Refractory Trial in United States

Completed
Has Results
  • Non-Hodgkin's Lymphoma, Relapsed
  • +8 more
  • PBCAR20A
  • +2 more
  • Duarte, California
  • +4 more
Jan 4, 2023

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell Trial in Worldwide (JNJ-75348780)

Recruiting
  • Lymphoma, Non-Hodgkin
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Birmingham, Alabama
  • +43 more
Jan 27, 2023

Lymphoma, Non-Hodgkin Trial in Worldwide (Fludarabine, Cyclophosphamide, JCAR017)

Recruiting
  • Lymphoma, Non-Hodgkin
  • Santa Monica, California
  • +36 more
Jan 25, 2023

Lymphoma, Non-Hodgkin Trial in Worldwide (CC-99282, Rituximab, Obinutuzumab)

Recruiting
  • Lymphoma, Non-Hodgkin
  • Los Angeles, California
  • +86 more
Jan 23, 2023

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular Trial in United States (JCAR017, Durvalumab,

Active, not recruiting
  • Lymphoma, Non-Hodgkin
  • +2 more
  • JCAR017
  • +7 more
  • Duarte, California
  • +17 more
Jan 13, 2023

Lymphoma, Non-Hodgkin Trial in Worldwide (Standard of Care, JCAR017)

Active, not recruiting
  • Lymphoma, Non-Hodgkin
  • Standard of Care
  • JCAR017
  • Phoenix, Arizona
  • +78 more
Jan 13, 2023

Lymphoma, Non-Hodgkin Trial in Germany, Puerto Rico, United States (Lenalidomide, Rituximab)

Active, not recruiting
  • Lymphoma, Non-Hodgkin
  • Tucson, Arizona
  • +114 more
Jan 11, 2023

Lymphoma, Non-Hodgkin Trial in Worldwide (CC-96673)

Recruiting
  • Lymphoma, Non-Hodgkin
  • Minneapolis, Minnesota
  • +11 more
Nov 18, 2022

Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors Trial in United States (Crizotinib, Palbociclib, Sunitinib)

Recruiting
  • Lymphoma, Non-Hodgkin
  • +2 more
  • Birmingham, Alabama
  • +125 more
Nov 21, 2022

CB-Long-Term Safety Study (CB-LTSS)

Enrolling by invitation
  • Lymphoma, Non-Hodgkin
  • +7 more
  • Allogeneic CAR-T therapy
  • Irvine, California
  • +3 more
Nov 18, 2022

Lymphoma, Follicular, Lymphoma, Mantle-Cell, Marginal Zone Lymphoma Trial in United States (ADI-001, Fludarabine,

Recruiting
  • Lymphoma, Follicular
  • +5 more
  • ADI-001
  • +2 more
  • Stanford, California
  • +6 more
Oct 19, 2022

Lymphoma, Non-Hodgkin, Relapsed Non Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma Trial in United States (CB-010,

Recruiting
  • Lymphoma, Non-Hodgkin
  • +6 more
  • CB-010
  • +2 more
  • Scottsdale, Arizona
  • +7 more
Aug 19, 2022

Allogeneic Gamma Delta (?d) CAR T Cells

Enrolling by invitation
  • Lymphoma, Follicular
  • +5 more
  • ADI-001
  • Stanford, California
  • +4 more
Jun 7, 2022

Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Mixed-Phenotype Leukemia Trial in United States (BMF-219)

Recruiting
  • Acute Myeloid Leukemia
  • +12 more
  • Los Angeles, California
  • +6 more
Jun 1, 2022

Lymphoma, B-Cell, Lymphoma, Non-Hodgkin, Leukemia, B-cell Trial in Worldwide (Ibrutinib)

Enrolling by invitation
  • Lymphoma, B-Cell
  • +4 more
  • Burbank, California
  • +90 more
Mar 31, 2022

Lymphoma, Non-Hodgkin Trial in United States (Hematopoietic Stem Cell Transplant)

Completed
Has Results
  • Lymphoma, Non-Hodgkin
  • Hematopoietic Stem Cell Transplant
  • Duarte, California
  • +20 more
Dec 7, 2021

Lymphoma, Hodgkin's Disease, Relapse Trial in Houston (TGFbeta resistant LMP-specific CTLs)

Active, not recruiting
  • Lymphoma
  • +3 more
  • TGFbeta resistant LMP-specific CTLs
  • Houston, Texas
  • +1 more
Dec 8, 2021

Lymphoma Epidemiology of Outcomes Cohort Years 6-10

Enrolling by invitation
  • Lymphoma, Non-Hodgkin
    • Miami, Florida
    • +7 more
    Aug 20, 2021

    FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large

    Completed
    • Lymphoma
    • +2 more
    • FLT-PET/CT
    • +2 more
    • Los Angeles, California
    • +3 more
    May 6, 2021

    Disease, Hodgkin, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Non-Hodgkin Trial in Worldwide (brentuximab vedotin)

    No longer available
    • Disease, Hodgkin
    • +3 more
    • brentuximab vedotin
    • Stanford, California
    • +30 more
    Sep 17, 2020

    Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse Trial in Worldwide (PF-05082566, rituximab)

    Completed
    Has Results
    • Lymphoma, Non-Hodgkin
    • +6 more
    • Duarte, California
    • +41 more
    Mar 4, 2020

    Chronic Lymphocytic Leukemia, Lymphoma, Non-Hodgkin Trial in United States (Idelalisib)

    Terminated
    Has Results
    • Chronic Lymphocytic Leukemia
    • Lymphoma, Non-Hodgkin
    • Huntsville, Alabama
    • +17 more
    Aug 22, 2019

    Leukemia, Lymphocytic, Acute, Leukemia, Myelocytic, Acute, Leukemia, Myeloid, Chronic Trial in Houston (procedure, drug,

    Completed
    Has Results
    • Leukemia, Lymphocytic, Acute
    • +3 more
    • Expanded allogeneic cord blood (CB)
    • +8 more
    • Houston, Texas
      University of Texas MD Anderson Cancer Center
    Apr 10, 2019

    Lymphoma, Non-Hodgkin Trial in Worldwide (Inotuzumab ozogamicin, Rituximab, rituximab + gemcitabine)

    Terminated
    Has Results
    • Lymphoma, Non-Hodgkin
    • Inotuzumab ozogamicin
    • +3 more
    • Burbank, California
    • +176 more
    Dec 19, 2018